Analysis of efficacy of the SGLT2 inhibitor alone or in combination with the DPP-4 inhibitor on urinary and plasma DPP-4 activities in obese patients with type 2 diabetes.

Analysis of efficacy of the SGLT2 inhibitor alone or in combination with the DPP-4 inhibitor on urinary and plasma DPP-4 activities in obese patients with type 2 diabetes. - Analysis of efficacy of the SGLT2 inhibitor alone or in combination with the DPP-4 inhibitor on urinary and plasma DPP-4 activities in obese patients with type 2 diabetes.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019098

Enrollment

100

Registered

2015-09-29

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Canagliflozin100mg(24weeks),Teneligliptin(12weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) HbA1c levels of >=7.0% to <=10.0% (NGSP) 2) BMI >=25 kg/m2 3) Under treatment with fixed diet, exercise ,medication therapy>=4 weeks 4) Age >=20 to <75 years 5) Submission of written informed consent for participation in this study

Exclusion criteria

Exclusion criteria: 1) Under treatment with SGLT2 inhibitor,DPP-4 inhibitor, insulin, or GLP-1 analog 2) Severe ketosis, diabetic coma, or diabetic precoma within the past six months 3) Type 1 diabetes 4) Pituitary gland dysfunction, adrenal gland dysfunction 5) Severe infectious diseases, pre or post surgery, and serious trauma 6) Pregnant women, women suspected of being pregnant, or lactating women 7) Severe renal function disorder (eGFR < 45) 8) Severe liver function disorder 9) History of malignant tumor 10) Cardiac arrest (class of IV in NYHA) 11) Self-contained device such as pacemakers 12) Wearable devices such as Holter electrocardiographs 13) Implantable metallic medical devices

Design outcomes

Primary

Measure	Time frame
Changes in HbA1c, and urinary and plasma DPP-4 activities after 12 weeks of treatment with canagliflozin	—

Secondary

Measure	Time frame
Change in glycemic, insulinemic, lipid, and hepatic parameters, body weight, visceral fat area, urinary and plasma DPP-4 activities, and blood pressure and heart rate after treatment with canagliflozin alone or in combination with teneligliptin.	—

Countries

Japan

Contacts

Public ContactEriko Kawamoto

University of the Ryukyus Hospital Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatolog

ikyoku@ryudai2nai.com098-895-3331

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026